-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310

Benzinga·11/03/2026 18:03:26
Listen to the news
JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $300 to $310.